Morepen Laboratories Secures ₹8.25 Billion Order

In a significant development for India’s pharmaceutical industry, Morepen Laboratories Ltd. announced that it has secured an order valued at ₹8.25 billion (₹825 crore). The order is expected to enhance the company’s revenue pipeline and expand its footprint in both domestic and international markets.

Morepen, known for its OTC healthcare products, diagnostics, and APIs (Active Pharmaceutical Ingredients), has been steadily diversifying its portfolio to meet rising global demand. The new order underscores the company’s ability to deliver at scale while maintaining quality standards, aligning with India’s broader push to strengthen its pharmaceutical exports.

Industry experts suggest that this deal could further consolidate Morepen’s market position and provide a strong boost to its growth trajectory in FY2026.

Key Highlights

• Order Value: ₹8.25 billion secured by Morepen Laboratories.
• Business Impact: Strengthens revenue pipeline and market presence.
• Product Range: OTC healthcare, diagnostics, APIs, and wellness solutions.
• Strategic Significance: Enhances domestic and global footprint.
• Investor Confidence: Signals robust demand and growth momentum.

This milestone reflects Morepen’s commitment to innovation, scale, and quality, positioning it as a key player in India’s pharmaceutical growth story.

Sources: Trendlyne Marketwatch; Economic Times Pharma Coverage; Business Standard Reports